[Long-term treatment of angle-closure glaucoma with bupranolol eye drops (author's transl)].
In this study we report on the effect of Bupranolol eye drops on 10 patients who, prior to treatment, experienced decompensation of their glaucoma in spite of the use of miotics or who were not given biotics treatment because of their occupation or because of severe subjective complaints. Treatment with Bupranolol is given for six months and results in clear reduction of intraocular pressure in all patients, so that satisfactory control can be achieved with Bupranolol eye drops either alone or in combination with a miotic agent. As a rule, Bupranolol is tolerated well by all patients.
D000328:Adult; D000368:Aged; D002046:Bupranolol / Q000627:therapeutic use*; D005260:Female; D005901:Glaucoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*
D011412:Propanolamines; D002046:Bupranolol
Langzeitbehandlung bei Engwinkelglaukom mit Bupranolol-Augentropfen.